Found: 6
Select item for more details and to access through your institution.
PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepitheliomalike carcinoma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.951817
- By:
- Publication type:
- Article
Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 1, p. 396, doi. 10.1002/cam4.4925
- By:
- Publication type:
- Article
An integrated biomarker of PD‐L1 expression and intraepithelial CD8<sup>+</sup> T cell infiltration was associated with the prognosis of lung cancer patients after intracranial resection of brain metastases.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 13, p. 1948, doi. 10.1111/1759-7714.14473
- By:
- Publication type:
- Article
High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 19, p. 2564, doi. 10.1111/1759-7714.14137
- By:
- Publication type:
- Article
Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma.
- Published in:
- Thoracic Cancer, 2020, v. 11, n. 2, p. 346, doi. 10.1111/1759-7714.13271
- By:
- Publication type:
- Article
Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma‐like carcinoma.
- Published in:
- Clinical & Translational Immunology, 2024, v. 13, n. 6, p. 1, doi. 10.1002/cti2.1515
- By:
- Publication type:
- Article